Staar Surgical Co: insider trades · United States · SEC (Form 4)

About Staar Surgical Co

STAAR Surgical Co (NASDAQ: STAA) is a U.S.-based medical device company focused on ophthalmic surgery. Founded in 1982, the company has built its franchise around implantable lenses for vision correction and is headquartered in Lake Forest, California, United States. For international investors, STAAR is best viewed as a specialized healthcare technology name with exposure to structural demand trends in refractive surgery and to patient preferences for premium vision-correction options. The company’s core business is the design, development, manufacturing, and sale of implantable collamer lenses (ICLs) and the related delivery systems used to implant them. Its flagship offering is the EVO family of lenses, built on its proprietary Collamer material and primarily used to treat myopia, with certain versions addressing additional refractive needs. STAAR’s products are positioned as premium alternatives to corneal laser procedures, targeting surgeons, hospitals, ambulatory surgery centers, and, in some markets, distributors. The business is concentrated in one reportable segment: ophthalmic surgical products. In competitive terms, STAAR occupies a differentiated niche in refractive eye surgery. Rather than competing as a broad-based medtech platform, it focuses on a category where clinical expertise, surgeon adoption, product performance, and long-term brand credibility matter significantly. That specialization supports pricing power and product identity, but it also creates concentration risk. Demand can be affected by macroeconomic conditions, channel inventory swings, regulatory dynamics, and the pace of adoption in key markets. STAAR sells globally, and its footprint is international. Historically, China has been an especially important market, which has made the company sensitive to changes in local demand, distributor inventories, and broader market conditions there. At the same time, the company maintains operations beyond the United States, including manufacturing-related capabilities in Switzerland. This global structure gives STAAR access to multiple growth markets, but it also means execution must be carefully managed across regions. Recent developments suggest a transitional phase for the business. Company disclosures in 2025 and 2026 point to leadership changes, tighter cost control, supply-chain optimization, and a renewed emphasis on commercial discipline and sustainable profitability. The most recent reported results in 2026 highlighted a recovery in gross margin and more resilient performance outside China, while management also emphasized strategic resets intended to restore growth. In that context, STAAR Surgical on NASDAQ remains a focused ophthalmic franchise with meaningful upside tied to execution, product adoption, and a successful turnaround in its key geographic markets.